MAGED2: a novel p53-dissociator.

MAGED2: a novel p53-dissociator. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

MAGED2: a novel p53-dissociator. Abstract Text:

Chris Papageorgio,Rainer Brachmann,Jue Zeng,Robert Culverhouse,Wanghai Zhang,Howard McLeod,Chris Papageorgio,Rainer Brachmann,Jue Zeng,Robert Culverhouse,Wanghai Zhang,Howard McLeod,

The tumor suppressor protein p53 is a transcription factor that is frequently mutated in human cancers. In response to DNA damage, unmutated or wild-type (wt) p53 protein is stabilized and activated by post-transcriptional modifications that enable it to induce either apoptosis or cell cycle arrest. Using a yeast p53-dissociator assay, we identified MAGED2 as a potential negative regulator of wt p53 activity. Subsequently, using co-immunoprecipitation and reporter gene assays in human cultured cells that are often adopted for functional analysis of p53 we demonstrated that MAGED2 interacted physically with p53 and modified its activity. Finally, we were able to illustrate expression of both p53 and MAGED2 within the same subcellular compartment, i.e. either nucleus or cytoplasm, in 2,682 human cancer tissue specimens using a common cancer tissue microarray and antibodies against MAGED2 and p53. The present results implicate MAGED2, a novel protein, as a p53-dissociator.

MAGED2: a novel p53-dissociator. Publishing Authors By Initials

C Papageorgio,R Brachmann,J Zeng,R Culverhouse,W Zhang,H McLeod,C Papageorgio,R Brachmann,J Zeng,R Culverhouse,W Zhang,H McLeod,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

MAGED2: a novel p53-dissociator. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: International journal of oncology

VOLUME: 31

Page Numbers: 1205-11

Journal Abbreviation: Int. J. Oncol.

ISSN: 1019-6439

DAY: 3

MONTH: Nov

YEAR: 2007

MAGED2: a novel p53-dissociator. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9306042

MAGED2: a novel p53-dissociator. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: MAGED2: a novel p53-dissociator. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for MAGED2: a novel p53-dissociator.

AFFILIATION: Hematology and Medical Oncology, Ellis Fischel Cancer Center, University of Missouri-Columbia, Columbia, MO 65203, USA. papageorgioc@health.missouri.edu

Country: Greece

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

MAGED2: a novel p53-dissociator Related Publications

• CEPH individuals are representative of the European American population: implications for pharmacogenetics.
• Choice in fertility preservation in girls and adolescent women with cancer.
• Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome.
• Cr05 bacteria not commonly associated with human faeces implicated in etiology of pouchitis.
• DNA repair pathway profiling and microsatellite instability in colorectal cancer.
• Dominantly-inherited lop ears.
• Drug pathways: one gene is not enough.
• Epitheliotropic lymphoma in a squirrel (Sciurus sp.).
• Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias.
• Genetic variation in the B-type natiuretic peptide pathway affects BNP levels.
• Graying anatomy? Toward molecular tumor characterization.
• Improved outcome due to increased experience and individualized management of leaks after ileal pouch-anal anastomosis.
• Instilling a culture of evidence-based surgery in Canada.
• Intelligent alarm processing into clinical knowledge.
• MAGED2: a novel p53-dissociator.
• PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
• Perceived dangerousness of children with mental health problems and support for coerced treatment.
• Pharmacogenetics and oncology treatment for breast cancer.
• Physiology and pharmacology of the brushtail possum gastrointestinal tract: Relationship to the human gastrointestinal tract.
• Plus ça change...
• Premenstrual symptomatology, alcohol consumption, and family history of alcoholism in women with premenstrual syndrome.
• Primum non nocere: adverse drug events must be taken seriously.
• Reversal of lower limb venous and lymphatic pooling by passive non-invasive calf muscle pump stimulation.
• Should DPD analysis be required prior to prescribing fluoropyrimidines?
• Success and failure of single-modality treatment for early prostate cancer.
• The effective management of biochemical recurrence in patients with prostate cancer.
• The emergence of radioimmunoscintigraphy for prostate cancer.
• The enantioselective synthesis of APTO and AETD: polyhydroxylated beta-amino acid constituents of the microsclerodermin cyclic peptides.
• UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
• Vibromyographic quantification of voluntary isometric contractile force in the brachioradialis.